azeliragon (TTP488) / Cantex Pharma 
Welcome,         Profile    Billing    Logout  
 22 Diseases   6 Trials   6 Trials   188 News 


123»
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Review, Journal:  Deconstructing the RAGE signaling maze: the molecular key to opening a new dimension of ovarian anti-aging. (Pubmed Central) -  Apr 21, 2026   
    We highlight therapeutic strategies targeting RAGE, including small-molecule inhibitors (Azeliragon and FPS-ZM1), soluble RAGE decoys and natural compounds, which show promise in restoring ovarian reserve and hormonal balance in preclinical models...Beyond reproductive health, RAGE's role in aging and metabolic disorders underscores its potential as a cross-disciplinary biomarker and therapeutic target. By bridging molecular mechanisms with clinical applications, this work provides a framework for developing precision therapies to combat ovarian aging, with implications for endocrinology, oncology and geroscience.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Journal:  Phycocyanobilin as a Functional Food-Derived Nutraceutical Candidate for Modulating the RAGE/NOX4 Axis in Neurodegenerative Disorders. (Pubmed Central) -  Mar 7, 2026   
    The overall protective profile of PCB was comparable to that observed with TTP488 at the level of downstream pathway modulation. These findings suggest that PCB mitigates glycation-associated neuronal injury through coordinated regulation of oxidative, ER stress, and mitochondrial apoptotic pathways linked to RAGE/NOX4 signaling, supporting further investigation of PCB as a functional food-derived bioactive in metabolic stress-related neurodegeneration.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment open:  CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Mar 4, 2026   
    P1/2,  N=18, Recruiting, 
    These findings suggest that PCB mitigates glycation-associated neuronal injury through coordinated regulation of oxidative, ER stress, and mitochondrial apoptotic pathways linked to RAGE/NOX4 signaling, supporting further investigation of PCB as a functional food-derived bioactive in metabolic stress-related neurodegeneration. Not yet recruiting --> Recruiting
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Trial completion date, Trial primary completion date:  CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Feb 5, 2026   
    P1/2,  N=18, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
  • ||||||||||  Trial completion date, Trial primary completion date:  RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) -  Dec 25, 2025   
    P1/2,  N=48, Recruiting, 
    Therefore, RAGE antagonism significantly reduced ischemic brain damage and neuroinflammation in diabetic cerebral ischemia, offering a promising therapeutic strategy. Trial completion date: Oct 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Dec 2026
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Azeliragon has significant activity against acute myeloid leukemia blasts () -  Dec 5, 2025 - Abstract #ASH2025ASH_8739;    
    Synergy analysis of OCI-AML3 cells with Combenefit software demonstrated high synergy scores when AZE was combined with cytarabine or venetoclax, medium synergy scores when combined with daunorubicin, and antagonism when combined with azacitidine...The relapse patients included 1 with relapse after 2 bone marrow transplants, 1 with relapse after 7 lines of treatment (including Revumenib), and another 1 with relapse after Revumenib...We conclude that AZE shows promising single agent activity in AML with potential for synergistic combinations with standard agents. Clinical investigation of AZE for the treatment of AML is warranted.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Journal:  RAGE signaling pathway in glioblastoma and cognitive decline: Insights into inflammatory mechanisms and therapeutic implications. (Pubmed Central) -  Nov 16, 2025   
    Collectively, the evidence highlights the RAGE signaling as one of the central modulators of GBM progression and RT-induced cognitive decline through NF-?B, JAK/STAT, and MAPK activation. Future strategies that selectively disrupt pathological RAGE signaling, while sparing physiological functions, may provide transformative therapeutic avenues for patients facing the dual burden of glioblastoma and radiation-induced neurotoxicity.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Trial primary completion date:  ADORATION: Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (clinicaltrials.gov) -  Nov 14, 2025   
    P1/2,  N=46, Recruiting, 
    Future strategies that selectively disrupt pathological RAGE signaling, while sparing physiological functions, may provide transformative therapeutic avenues for patients facing the dual burden of glioblastoma and radiation-induced neurotoxicity. Trial primary completion date: Oct 2025 --> Mar 2027
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Trial completion date, Trial primary completion date:  Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Jul 2, 2025   
    P1,  N=12, Not yet recruiting, 
    Enhancing our comprehension of neuronal death mechanisms could elucidate disease pathogenesis, offer insights for therapeutic approaches, and aid in developing modified animal models of AD. Trial completion date: May 2029 --> Apr 2030 | Trial primary completion date: Oct 2027 --> Oct 2028
  • ||||||||||  Trial completion date, Trial primary completion date:  RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) -  May 23, 2025   
    P1/2,  N=48, Recruiting, 
    The role of RAGE in EMT was studied in cells pretreated with RAGE antagonists (FPS-ZM1 or azeliragon), followed by cotreatment with TGF-?2 for 48 Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Mar 2025 --> Oct 2025
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment open:  Concurrent Azeliragon With Craniospinal Irradiation (clinicaltrials.gov) -  Mar 5, 2025   
    P1,  N=32, Recruiting, 
    Enrollment is currently open for level L4. Not yet recruiting --> Recruiting
  • ||||||||||  Trial completion date, Trial primary completion date:  RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) -  Dec 26, 2024   
    P1/2,  N=48, Recruiting, 
    Compound 2g exhibits potent inhibition of the AGE2-BSA/sRAGE interaction (IC50 = 22 Trial completion date: Nov 2024 --> Apr 2025 | Trial primary completion date: Nov 2024 --> Mar 2025
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment closed:  CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Nov 12, 2024   
    P1/2,  N=18, Active, not recruiting, 
    Trial completion date: Nov 2024 --> Apr 2025 | Trial primary completion date: Nov 2024 --> Mar 2025 Recruiting --> Active, not recruiting
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment closed:  Azeliragon in MGMT Unmethylated Glioblastoma (clinicaltrials.gov) -  Sep 5, 2024   
    P2,  N=30, Active, not recruiting, 
    N=21 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Journal:  Involvement of RAGE in radiation-induced acquisition of malignant phenotypes in human glioblastoma cells. (Pubmed Central) -  Jul 28, 2024   
    Both phenotypes were suppressed by specific inhibitors of RAGE (FPS-ZM1 and TTP488) or by knockdown of RAGE...In addition, ?-irradiation-induced phosphorylation of STAT3 was suppressed by RAGE inhibitors, and a STAT3 inhibitor suppressed ?-irradiation-induced enhancement of cell migration, indicating that STAT3 is involved in the migration enhancement downstream of RAGE. Our results suggest that HMGB1-RAGE-STAT3 signaling is involved in radiation-induced enhancement of GBM cell migration, and may contribute to GBM recurrence by promoting metastasis and invasion.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment change, Trial completion date, Trial primary completion date:  Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Jun 13, 2024   
    P1/2,  N=30, Recruiting, 
    Our results suggest that HMGB1-RAGE-STAT3 signaling is involved in radiation-induced enhancement of GBM cell migration, and may contribute to GBM recurrence by promoting metastasis and invasion. N=18 --> 30 | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
  • ||||||||||  Herceptin (trastuzumab) / Roche, azeliragon (TTP488) / Cantex Pharma, Perjeta (pertuzumab) / Roche
    RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE). (Hall A; Poster Bd #: 207a) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1347;    
    P1/2
    In Cohort 4, 6 patients will receive dose dense doxorubicin and cyclophosphamide (ddAC)...As of 2/1/24, 4 patients have been enrolled, with 4 undergoing screening. At the completion of this trial, we plan a randomized trial to evaluate the role of TTP488 to decrease cardiotoxicity, cancer related cognitive decline and disease recurrence.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Trial primary completion date:  CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Feb 15, 2024   
    P1/2,  N=18, Recruiting, 
    Our results provide novel insights into the role of the AGE-RAGE axis in skeletal muscle aging, and future work is warranted on the potential application of S100b as a pro-regenerative factor in aged skeletal muscle. Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Journal:  Macrophage RAGE activation is proinflammatory in NASH. (Pubmed Central) -  Jan 4, 2024   
    FFC mice that received a pharmacological inhibitor of RAGE (TTP488), and myeloid-specific RAGE KO mice (RAGE-MKO) had attenuated liver injury associated with a reduced accumulation of RAGE+ recruited macrophages...Correspondingly, the secretome of ligand-stimulated bone marrow derived macrophages from RAGE-MKO mice had an attenuated capacity to activate CD8+ T cells. Our data implicate RAGE as what we propose to be a novel and potentially targetable mediator of the proinflammatory signaling of recruited macrophages in NASH.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment open:  Azeliragon in MGMT Unmethylated Glioblastoma (clinicaltrials.gov) -  Oct 27, 2023   
    P2,  N=30, Recruiting, 
    Our data implicate RAGE as what we propose to be a novel and potentially targetable mediator of the proinflammatory signaling of recruited macrophages in NASH. Not yet recruiting --> Recruiting
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment open, Trial initiation date:  CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Sep 15, 2023   
    P1/2,  N=18, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Sep 2023